CD4 and AIDS: The Strategic Timing of Antiretroviral Therapy (START) study found that patients who began antiretroviral therapy (ART) when CD4+ cell counts were above 500 cells per cubic millimeter had a 57% reduced risk of AIDS and serious non-AIDS health outcomes than patients who started ART after CD4+ cell counts dropped below 350 cells/mm3 [21].